Drug Profile
Espindolol
Alternative Names: AGI-001; S-pindolol - AGI TherapeuticsLatest Information Update: 31 Jul 2015
Price :
$50
*
At a glance
- Originator AGI Therapeutics
- Class Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia
Most Recent Events
- 19 Feb 2007 Discontinued - Phase-II for Irritable bowel syndrome in Ireland (PO)
- 19 Feb 2007 Discontinued - Phase-II for Non-ulcer dyspepsia in United Kingdom (PO)
- 03 Oct 2006 Interim results from a phase II clinical trial in patients with irritable bowel syndrome have been added to the adverse events and Digestive System Disorders therapeutic trials sections